June 17, 2015

Dear California STD Controllers,

On June 5, 2015, the Centers for Disease Control and Prevention (CDC) released the new 2015 Sexually Transmitted Diseases (STD) Treatment Guidelines (http://www.cdc.gov/std/tg2015/default.htm). Listed below are highlights of the key screening and treatment recommendations; yellow stars indicate items that are significantly changed from the 2010 Guidelines. A national webinar describing the 2015 CDC STD Treatment Guidelines is scheduled for June 22, 2015. Please mark your calendar and register at the following link: https://cc.readytalk.com/cc/s/registrations/new?cid=9twwtzwp4u4m.

Chlamydia and Gonorrhea Screening:

- Sexually active women less than age 25 are recommended to receive annual chlamydia and gonorrhea screening\(^1\).

STD Screening in Men Who Have Sex with Men (MSM):

- In addition to HIV, syphilis serology, and urine chlamydia and gonorrhea screening, pharyngeal gonorrhea and anal chlamydia and gonorrhea screening are recommended in sexually active MSM regardless of reported condom use.
- \(\star\) Hepatitis C testing (HCV) is now recommended at least annually in MSM with HIV infection; more frequent testing is recommended based on HCV prevalence, high risk behavior, ulcerative STDs, or STD-related proctitis.

Male Urethritis Diagnosis:

- \(\star\) Point-of-care diagnostic criteria for male urethritis changed to \(\geq 2\) white blood cells (WBCs) per oil immersion field (previously \(\geq 5\) WBCs).

\(^1\) U.S. Preventive Services Task Force (USPSTF) recommends chlamydia and gonorrhea screening in sexually active women less than age 25 as grade “B” recommendation.
Point-of-care diagnostic tests recommended for diagnosis now include methylene blue or gentian violet stain microscopy of urethral secretions, in addition to Gram stain microscopy of urethral secretions, first void urine with microscopy, and leukocyte esterase test.

**Gonorrhea Treatment:**

- Recommended dual antibiotic treatment for uncomplicated gonococcal infections:
  - **CEFTRIAXONE 250 MG INTRAMUSCULAR (IM) plus AZITHROMYCIN 1 GRAM (g) ORALLY**
    - Doxycycline moved to an alternative co-treatment
    - Azithromycin 2 g orally no longer recommended as single drug therapy in cephalosporin-allergy
    - Dual treatment with cefixime 400 mg orally plus azithromycin 1 g orally remains acceptable as expedited partner treatment for gonorrhea
- New gonorrhea treatment options in cases of cephalosporin-allergy, IgE-mediated penicillin allergy, or treatment failure to recommended regimen:
  - Gentamicin 240 mg IM + azithromycin 2 g orally, or
  - Gemifloxacin 320 mg orally + azithromycin 2 g orally
- Routine test of cure now recommended only for individuals who received an alternative treatment for pharyngeal gonorrhea; test of cure interval has been extended to 14 days after treatment to reduce false positive results (previously 7 days)

**Suspected Gonorrhea Treatment Failures:**

- Most treatment failures are due to reinfection; if reinfection likely, treat with recommended regimen (ceftriaxone + azithromycin)
- If true treatment failure is suspected:
  - Obtain culture for antibiotic susceptibility testing
  - If treatment failure to alternative regimen (cefixime + azithromycin), treat with ceftriaxone 250 mg IM + azithromycin 2 g orally
  - If treatment failure to recommended regimen, treat with gentamicin + azithromycin OR gemifloxacin + azithromycin

---

2 California Gonorrhea Treatment Guidelines -- Suspected Gonorrhea Treatment Failure are available at: [http://www.cdph.ca.gov/pubsforms/Guidelines/Pages/CAGuidelinesGonorrheaTxFailure.aspx](http://www.cdph.ca.gov/pubsforms/Guidelines/Pages/CAGuidelinesGonorrheaTxFailure.aspx)

3 Contact CDPH clinician warm line if you have difficulty obtaining access to culture: 510-620-3400
STD Controllers
June 17, 2015

- Report to local or state health department
- Test of cure 7-14 days after retreatment
- All partners in last 60 days should be tested with culture and empirically treated using the same regimen used for the patient

Chlamydia Treatment:
- Amoxicillin moved to alternative regimen for treatment of chlamydia in pregnancy
- Increasing data that doxycycline is more effective than azithromycin for rectal chlamydia infection; no change to rectal chlamydia treatment
- Delayed-release doxycycline (Doryx) 200 mg daily for 7 days may be an alternative regimen for treatment of urogenital chlamydia infection

Expedited Partner Therapy (EPT):4
- EPT for chlamydia and gonorrhea strongly encouraged
- For chlamydia, azithromycin should be provided; for gonorrhea, dual treatment with cefixime + azithromycin should be provided
- Preferred approach is to provide appropriately packaged medication directly to patients to give to their partners; prescriptions are discouraged as many people do not fill prescriptions

Syphilis:
- For pregnant women, benzathine penicillin doses for treatment of late latent syphilis must be administered at 7-day intervals; if a dose is missed or late, the entire series must be restarted
- If clinical signs of central nervous system involvement (neurologic, ocular, auditory, meningitis, stroke) are observed, a cerebrospinal fluid (CSF) examination should be performed

Human Papillomavirus (HPV) Vaccine:
- CDC guidance is aligned with the Advisory Committee on Immunization Practices (ACIP), and includes recently approved 9-valent HPV vaccine:

---

Routine vaccination at age 11 or 12 years old; vaccination is recommended through age 26 for females and through age 21 for males not previously vaccinated

Vaccination is recommended for MSM and immunocompromised men through age 26

Vaccination of females is recommended with the bivalent, quadrivalent, or nonavalent HPV vaccine; vaccination of males is recommended with quadrivalent or nonavalent HPV vaccine

Genital Warts:
- Imiquimod 3.75% is now available as treatment option
- Podophyllin resin was demoted to an alternative regimen after reports of serious toxicities

Trichomonas:
- The use of highly sensitive and specific tests is recommended for detecting trichomonas; improved diagnostic testing is now available, including nucleic acid amplification tests (NAAT), which are highly sensitive among women
- Retest all sexually active women within 3 months after treatment
- Some emerging reports about nitroimidazole resistance but no changes to previously recommended treatment

New Sections:
- Preexposure Prophylaxis (PrEP) for HIV
- Transgender Men and Women
- Hepatitis C
- Mycoplasma genitalium
  - No Food and Drug Administration (FDA) cleared test
  - Common cause of nongonococcal urethritis (NGU) and recurrent urethritis
  - Moxifloxacin is more effective than azithromycin for the treatment of *M. genitalium*; doxycycline is largely ineffective against *M. genitalium*

For clinical questions related to the 2015 CDC STD Treatment Guidelines, please contact Dr. Julie Stoltey at: Juliet.Stoltey@cdph.ca.gov or (510) 620-3408.
Within the next few weeks, we will print and bind copies of the complete 2015 CDC STD Treatment Guidelines and mail to STD controllers. We will also be updating the laminated one-page treatment guidelines summaries and other clinical job aids. If your STD program would like to request additional copies of these materials, please contact Shalimar Sancho at Shalimar.Sancho@cdph.ca.gov.

As a reminder, we have a purchasing program to support local STD programs with medications, test kits, educational materials, and other items. The next opportunity to participate will be early spring 2016 for the 2016-17 fiscal year; however, if you have special requests or revisions to the purchasing list you already submitted for the 2015-16 fiscal year, please send an email to CDPHSTDProcurement@cdph.ca.gov or contact Matt Ayson at Matt.Ayson@cdph.ca.gov.

Sincerely,

Heidi Bauer, MD, MPH, MS
Chief, STD Control Branch

Cc:
James Watt, Division of Communicable Disease and Control
Karen Mark, Office of AIDS
Gil Chavez, Center for Infectious Diseases
Addie Aguirre, Maternal, Child and Adolescent Health Programs
Christina Moreno, Office of Family Planning
Eleanor Schwarz, Office of Family Planning
Sarah Brooks, Medi-Cal Managed Care
Tyrone Adams, Medi-Cal Managed Care
Anna Lee Amarnath, Medi-Care Managed Care
Janet Mohle-Boetani, California Department of Corrections and Rehabilitation
Sharla Smith, California Department of Education
Leah Northrop, California Conference of Local Health Officers
Robert Kim-Farley, California Conference of Local Health Officers
Barbara Cole, California Conference of Local Health Officers
Muntu Davis, California Conference of Local Health Officers
Jim McPherson, California Conference of Local AIDS Directors
Tamarra Jones, California Conference of Local AIDS Directors
Linda Ward, California Association of Public Health Laboratory Directors
Julie Rabinovitz, California Family Health Council
Alice Gandelman, California Prevention Training Center
April Pace, Cardea
William Smith, National Coalition of STD Directors
Karen Shea, Planned Parenthood Federation
Lynn Barclay, American Sexual Health Association
Gail Bolan, Centers for Disease Control and Prevention
Steven Shapiro, Centers for Disease Control and Prevention
Victoria Moody, Centers for Disease Control and Prevention